Foxy-5(Foxy-5) - 药物靶点：WNT5A_在研适应症：结肠癌_专利_临床

概要

基本信息

药物类型

合成多肽

别名

FOXY 5

靶点

WNT5A

作用机制

WNT5A调节剂(Wnt family member 5A modulators)

治疗领域

肿瘤消化系统疾病

在研适应症

结肠癌

非在研适应症

转移性乳腺癌结肠转移性腺癌转移性前列腺癌+ [1]

原研机构

Wntresearch AB

在研机构

Wntresearch AB

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C26H42N6O12S2

InChIKeyWFZPJYYCTSHDJI-ATIWLJMLSA-N

CAS号881188-51-8

序列信息

Sequence Code 80829

关联

1

项与 Foxy-5 相关的临床试验

NCT02655952 / Completed临床1期

Phase Ib Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacodynamic Response of Foxy-5 in Patients With Metastatic Breast-, Colon- or Prostate Cancer

The Wnt proteins belong to a family of proteins that have been demonstrated to play a role in the formation and dissemination of tumours. The present project focuses on the critical role of the Wnt-5a protein in the pathobiological processes that lead to metastatic cancer disease.
WntResearch has identified a formylated 6 amino acid peptide fragment, named Foxy-5, which mimick the effects of Wnt-5a to impair migration of epithelial cancer cells and thereby acting anti-metastatic.
The aim of the first clinical phase I study was to establish the recommended dose for a clinical phase II study and enable further development of Foxy-5 as a first in class anti-metastatic cancer drug. The study did not see any DLTs and therefore failed to reach maximum tolerated dose (MTD); no recommended phase II dose (RP2D) could therefore be established based on toxicity. The aim of this study is to continue to establish the safety profile of Foxy-5 in higher doses, and determine the RP2D for later stage development based on any observed DLT's/MTD and further analysis of the pharmacodynamic profile of Foxy-5 to determine the biological response dose (BRD).

开始日期2016-04-01

申办/合作机构

Wntresearch AB

100 项与 Foxy-5 相关的临床结果

登录后查看更多信息

100 项与 Foxy-5 相关的转化医学

登录后查看更多信息

100 项与 Foxy-5 相关的专利（医药）

登录后查看更多信息

52

项与 Foxy-5 相关的文献（医药）

2024-08-14·Journal of the American Chemical Society

A Cyanine Dye for Highly Specific Recognition of Parallel G-Quadruplex Topology and Its Application in Clinical RNA Detection for Cancer Diagnosis

Article

作者: Bai, Ruiyang ; Xiang, Junfeng ; Zhong, Fanru ; Zhou, Tianxing ; Tang, Yalin ; Sun, Ranran ; Liu, Jing ; Zhang, Boyang ; Yao, Li ; Jiang, Wenna ; Li, Qian ; Yang, Dawei ; Sun, Hongxia

G-quadruplex (G4), an unconventional nucleic acid structure, shows polymorphism in its topological morphology. The parallel G4 topology is the most prevalent form in organisms and plays a regulatory role in many biological processes. Designing fluorescent probes with high specificity for parallel G4s is important but challenging. Herein, a supramolecular assembly of the anionic cyanine dye SCY-5 is reported, which selectively identifies parallel G4 topology. SCY-5 can clearly distinguish parallel G4s from other G4s and non-G4s, even including hybrid-type G4s with parallel characteristics. The high specificity mechanism of SCY-5 involves a delicate balance between electrostatic repulsion and π-π interaction between SCY-5 and G4s. Using SCY-5, cellular RNA extracted from peripheral venous blood was quantitatively detected, and a remarkable increase in RNA G4 content in cancer patients compared to healthy volunteers was confirmed for the first time. This study provides new insights for designing specific probes for parallel G4 topology and opens a new path for clinical cancer diagnosis using RNA G4 as a biomarker.

2024-07-01·OPHTHALMIC AND PHYSIOLOGICAL OPTICS

Assessing neophyte response to daily disposable silicone hydrogel contact lenses: A randomised clinical trial investigation over one month

Article

作者: Garcia-Queiruga, Jacobo ; Noya-Padin, Veronica ; Pena-Verdeal, Hugo ; Ferreiro-Figueiras, Dolores ; Giraldez, Maria J ; Yebra-Pimentel, Eva

Abstract:

Objective:

This randomised clinical trial assessed the impact on symptoms, tear film dynamics and ocular surface integrity of daily disposable silicone‐hydrogel contact lenses (CLs) over a month, paying special attention to lid wiper epitheliopathy (LWE) and its implications for CL discomfort.

Methods:

Neophyte CL wearers (n = 44, 21.09 ± 5.00 years old) were randomly assigned to either the experimental (n = 24) or control group (n = 20). Participants assigned to the experimental group were required to wear daily disposable CLs for 1 month for at least 8 h/day and 6 days/week. All participants were healthy subjects (no history of ocular surgery or active ocular disease) with spherical refractive errors between −8.00 and +5.00 D and cylindrical power <0.75 D. At the baseline and 1‐month sessions, the Dry Eye Questionnaire 5 (DEQ‐5) was completed, together with the measurement of tear film osmolarity with the TearLab osmometer, tear meniscus height (TMH) and lipid layer pattern (LLP) using a slit‐lamp with Tearscope Plus attached, fluorescein break‐up time (FBUT), maximum blink interval (MBI), corneal staining with fluorescein under cobalt blue light and LWE with lissamine green under slit lamp and halogen white light.

Results:

At the baseline session, LWE showed a negative correlation with DEQ‐5 (r = −0.37, p = 0.02). Significant differences in FBUT and LWE (p = 0.04) and a positive correlation between LWE and DEQ‐5 (r = 0.49, p = 0.007) were observed at 1 month. Intrasession analysis at 1 month showed significant differences between the experimental and control groups in DEQ‐5, FBUT and LWE (all p ≤ 0.02). Intersession analysis in the experimental group showed variations in DEQ‐5, FBUT and LWE (all p ≤ 0.02) but no significant variation in the control group (all p ≥ 0.11).

Conclusion:

The presence of LWE was significantly correlated with higher symptom values in the DEQ‐5. Also, participants in the experimental group presented higher values of LWE after 1 month of CL wear, in comparison with the control group.

2024-02-01·Hepatology international

Clinical characteristics and prognosis of non-APAP drug-induced acute liver failure: a large multicenter cohort study

Article

作者: Li, Ning ; Liang, Qingsheng ; Zhu, Yun ; Liu, Hong-Li ; Wang, Jing ; Chen, Songhai ; Chen, Yu ; Sun, Ying ; Zou, Zhengsheng ; Huang, Ang ; Dang, Tong ; Han, Lin ; Wang, Xiaoxia ; Tian, Hui ; Teng, Guangju ; Xie, Huan ; Ji, Dong ; Zhao, Jun ; Yang, Yong-Feng ; Xu, Manman ; Chang, Binxia ; Lan, Xiaoqin ; Chen, Jinjun

Abstract:

Background:

There is growing recognition of natural history, complications, and outcomes of patients who develop non-acetaminophen (APAP) drug-induced acute liver failure (ALF). To clarify high-risk factors and develop a nomogram model to predict transplant-free survival (TFS) in patients with non-APAP drug-induced ALF.

Methods:

Patients with non-APAP drug-induced ALF from 5 participating centers were retrospectively analyzed. The primary endpoint was 21-day TFS. Total sample size was 482 patients.

Results:

Regarding causative agents, the most common implicated drugs were herbal and dietary supplements (HDS) (57.0%). The hepatocellular type (R ≥ 5) was the main liver injury pattern (69.0%). International normalized ratio, hepatic encephalopathy grades, the use of vasopressor, N-acetylcysteine, or artificial liver support system were associated with TFS and incorporated to construct a nomogram model (drug-induced acute liver failure-5, DIALF-5). The AUROC of DIALF-5 for 7-day, 21-day, 60-day, and 90-day TFS in the internal cohort were 0.886, 0.915, 0.920, and 0.912, respectively. Moreover, the AUROC of DIALF-5 for 21-day TFS had the highest AUROC, which was significantly higher than 0.725 of MELD and 0.519 of KCC (p < 0.05), numerically higher than 0.905 of ALFSG-PI but without statistical difference (p > 0.05). These results were successfully validated in the external cohort (147 patients).

Conclusions:

Based on easily identifiable clinical data, the novel DIALF-5 model was developed to predict transplant-free survival in non-APAP drug-induced ALF, which was superior to KCC, MELD and had a similar prediction performance to ALFSG-PI but is more convenient, which can directly calculate TFS at multiple time points.

100 项与 Foxy-5 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB13034

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
结肠癌	临床2期	西班牙	Wntresearch AB	2019-04-12
结肠转移性腺癌	临床1期	丹麦	Wntresearch AB	2016-04-01
结肠转移性腺癌	临床1期	英国	Wntresearch AB	2016-04-01
转移性前列腺癌	临床1期	丹麦	Wntresearch AB	2016-04-01
转移性前列腺癌	临床1期	英国	Wntresearch AB	2016-04-01
肿瘤转移	临床1期	丹麦	Wntresearch AB	2016-04-01
肿瘤转移	临床1期	英国	Wntresearch AB	2016-04-01
转移性乳腺癌	临床1期	丹麦	Wntresearch AB	2013-06-01